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G. MAZZARELLA” 
+A. Cardarelli Hospital, Diz@ion of~Pneumology and Allergology, Naples and *Institute of Respiratory Medicine, 
Medical School, Second University, Naples, Italy 
We examined the influence of higher than conventional doses of oxitropium bromide on formoterol-induced 
bronchodilation in patients with partially reversible stable COPD. Twenty outpatients inhaled one or two puffs of 
formoterol (1‘2 pg puff-!), or p@cebo. Two hours after inhalation, a dose-response curve to inhaled oxitropium 
bromide (100 pg puff-‘) or placebo was constructed using one puff, one puff, two puffs and two puffs, for a total 
cu$ulative dose of 600 pg oxitropium biomide. Doses were given at 20-min intervals and measurements made 15 
min after each dose. On six separate days, all patients received one of the following: (1) formoterol 12 pg + 
oxitropium bromide 600 pg, (2) formoterol 12 pg + placebo, (3) formotero124 pg + oxitropium bromide 600 pg, (4) 
formoterol 24 pg + placebo, (5) placebo + oxitropium bromide 600 pg, or (6) placebo + placebo. Both formoterol 
12 pg and 24 pg induced a good bronchodilation (formoterol 12 hg, 0.19-0.20 1; formoterol 24 pg 0.22-0.24 1). The 
dose-response curve of oxitropium, but not placebo, showed an evident increase in FEV1, with a further significant 
increase of respectively 0.087 1 and 0.082 1 after the formoterol 12 pg and formoterol 24 pg pre-treatment. This 
study shows that improved pulmonary function in patients with stable COPD may be achieved by adding 
oxitropium 400-600 pg to formoterol. There is not much difference in bronchodilation between combining 
oxitropium with formoterol 12 pg or 24 pg. In any case, formoterol24 pg alone seems sufficient to achieve the same 
bronchodilation induced by oxitropium 600 pg alone in most patients. 
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Introduction 
The analysis of the literature does not reveal a unequivocal 
predominance of a class of bronchodilator over others in 
the treatment of chronic obstructive pulmonary disease 
(COPD), but it seems to indicate that the combination of 
different broncholytic agents is currently the only strategy 
to adopt (1). Nevertheless, we must define the correct 
dosage of each drug that is currently used in association 
with other broncholytic agents. In fact, it is still not clear 
whether higher doses of monotherapy are better than 
combination therapy with lower doses of bronchodilators. 
In any case an additive effect may be expected when 
combining /?2-agonists and anticholinergic agents because 
they are distinct classes of drugs with different mechanisms 
of action (1). 
Long-acting &agonist bronchodilators (e.g. formoterol, 
salmeterol) are a new therapeutic option for COPD (l-3). 
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Both formoterol and salmeterol appear to be more effective 
than short-acting &agonists and anticholinergic agents in 
patients with stable COPD (46). However, the impact of 
long-acting P-agonists on combinations is still unclear. 
We have documented that in patients with COPD the 
addition of ipratropium bromide at clinically recommended 
dose (40 pg) does not produce any further bronchodilation 
than that achieved by using a long-acting &agonist 
(salmeterol 50 pg) alone, although the onset of action after 
the combination of the two drugs is faster than after 
salmeterol alone (7). It is possible that the subjects studied 
in that specific clinical situation were at the top of their 
bronchodilation response curve after inhalation of salme- 
terol, but it must also be stressed that the dose of 
ipratropium bromide needed to produce near maximal 
bronchodilation is several times higher than the customary 
dosage (8). Therefore, the full therapeutic potential of a 
combined long-acting /&-agonist plus an anticholinergic 
drug can only be established using doses higher than those 
currently recommended in the marketing of these agents. 
The present study was designed to examine the pd&ible 
influence of higher than conventional doses of ari antic- 
holinergic agent on formoterol-induced bronchodilation in 
patie$ts with stable and partially reversible COPD. 
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Patients and methods 
The study involved 20 outpatients (19 men and one woman) 
with co-existing moderate to severe COPD (baseline 
FEVi =21+63% predicted), but in a stable phase of 
disease, and with reversible airway obstruction (reversibility 
15 min after salbutamol 200 pg = + 15-3 1% from baseline) 
were enrolled. Other inclusion criteria were: ~50 years of 
age with a 20 or more-yr smoking history, AFEVi/predicted 
FEVi < 12%, and post-bronchodilator FEVi ~85%. Ex- 
clusion criteria were: current evidence of asthma as primary 
diagnosis, unstable respiratory disease requiring oral/ 
parenteral corticosteroids within the 4 weeks prior to 
commencing the study, upper or lower respiratory tract 
infection within the 4 weeks of screening visit, concurrent 
use of medications that affect COPD and evidence of 
alcohol abuse. All patients fulfilled the criteria proposed by 
the American Thoracic Society (9). 
The study, which was conducted according to the rules of 
the declaration of Helsinki, was performed using a 
randomized, single-blinded, cross-over design. 
Spirometric testing was performed immediately before 
inhalation of treatment and 2 h after inhalation of one or 
two puffs of formoterol (12 1.18 puff-‘), or placebo, which 
were inhaled from metered dose inhalers (MDI) and 
holding chamber (AeroChamber) with mouthpiece. 
Soon after the patients hadlperformed the post-treatment 
spirometries, a dose-response curve to inhaled oxitropium 
(100 pg puff- ‘) or placebo was constructed using one puff, 
one puff, two puffs and two puffs from a MD1 with spacer 
and mouthpiece for a total cumulative dose of 600 pg 
oxitropium. Doses were given at 20 min intervals and the 
measurements made 15 min after each dose. 
On six separate days, all patients received one of the 
following treatment combinations: 1. formoterol12 pg + oxi- 
tropium 600 pg, 2. formoterol12 pg + placebo, 3. formoterol 
24 pg + oxitropium 600 pg, 4. formotero124 pg + placebo, 5. 
placebo + oxitropium 600 pg, or 6. placebo + placebo. 
The maximum FEVi value of the dose-response curves to 
oxitropium bromide or placebo was chosen as the primary 
outcome variable. We did not estimate the power of the 
main analysis because this was a pilot study. The 
spirometric data for each treatment were analysed using 
Student’s t-test for paired variables. The mean responses to 
all of the treatments were also compared by multifactorial 
analysis of variance (ANOVA) in order to establish any 
significant overall effect. In the presence of a significant 
overall ANOVA, Duncan’s multiple range testing with 95% 
confidence limits was used to identify where the differences 
were significant. A probability level of PcO.05 was 
considered as being of significance for all tests. 
Results 
All patients completed the 6-day study. There were no 
significant differences between the baseline spirometric 
values of the six treatment groups (FEVr P = 0.994) 
Both doses of formoterol elicited a statistically significant 
(P<O.O5) increase in FEVi 2h after its inhalation (mean 
differences (1) = formoterol 12 pg before placebo: 0.20 (95% 
CI 0.140.26); for-moterol 12 pg before oxitropium: 0.19 
(95% CI 0.09-0.29); formoterol 24 pg before placebo: 0.22 
(95% CI 0.11-0.32); formoterol 24 pg before oxitropium: 
0.24 (95% CI 0.13-0.33)] whereas placebo did not modify 
the baseline values (Fig. 1). 
The dose-response curve of oxitropium, but not placebo, 
showed an evident increase in FEVi, with a further 
maximum increase of respectively 0.087 1 (95% CI 0.033- 
0.141) and 0.082 1 (95% CI 0.037-0.128) after the 
formoterol 12 pg and formoterol 24 pg pre-treatment 
(Fig. 2). These maximum FEVi values were statistically 
different (p< 0.05) from both their baseline and post- 
formoterol levels. The difference between the FEVi values 2 
h after formoterol 24 pg and oxitropium 600 after placebo 
(0.001 1; 95%. CI -0.069-e.067) was not significant 
(P=O.976). 
The mean difference between the highest oxitropium 
FEVi and highest placebo FEVi after formoterol 12 pg 
(0.091 1; 95% CI 0.0260.156 ) and formotero124 pg (0.083 
1; 95% CI 0.020-0.146) were statistically significant 
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FIG. 1. Baseline values and changes in FEVi 2 h after 
inhaled placebo (P) or formoterol (F) 12 ,ug or 24 pg. 
Values are mean. 0: F 12 pg + OB, ;: F 12 pg+P; n ;: F 
24 pg+OB; n : F 24 ~+PD P+OB; q : P+P. 
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FIG. 2. Mean (&-SD) dose-response curves to inhaled 
oxitropium bromide (OB) or placebo (P) constructed two 
hours after inhaling placebo (P) or formoterol (F) 12 pg 
or 24 pg for FEVi. +: F 12 pg + OB; tF 12 pg + P; f: 
F24pg+OB;+:F24pg+P;.-P+OB;+-P+P. 
(p c O.OS), whereas the mean difference between the highest 
oxitropium FEVi after formoterol 12 pg and formotero124 
pg (0.026 1; 95% CI -0.0924.142) was not statistically 
significant @ > 0.05). 
Discussion 
Use of combination therapy of a long-acting inhaled f12- 
agonist and an anticholinergic agent in COPD has not been 
sufficiently studied with respect to its effect on pulmonary 
function. In particular, a trial of an anticholinergic agent in 
patients with inadequate responsiveness to long-acting /?2- 
agonist, especially in those with severe airflow obstruction, 
is lacking in literature. 
In this study we have examined the bronchodilating 
impact of oxitropium on two doses of formoterol because it 
has been shown that, while the majority of 318 adults with 
reversible obstructive airways disease was adequately 
treated with formoterol 12 rug twice daily, a subgroup of 
patients with more severe airway obstruction required the 
24 pg dose (10). Moreover, we have used oxitropium 
bromide as the anticholinergic agent because it is an 
effective bronchodilator in COPD (11,12), exhibits a certain 
dose response relationship (13) and, more importantly, 
FEV, reaches a plateau after administration of a cumula- 
tive dose of only six puffs of oxitropium (600 pg) in patients 
with COPD (8). 
Our results indicate that improved pulmonary function in 
patients with stable COPD may be achieved by adding 
oxitropium 400-600 pg to formoterol. There is not much 
difference in bronchodilation between combining oxitro- 
pium with formoterol 12 fig or 24 pg. Formotero124 pg is in 
any case sufficient to achieve the same bronchodilation 
induced by oxitropium 600 pg alone in most patients. 
Larger studies are needed to determine whether the 
bronchodilation gained by using combination therapy may 
be maintained for a long period (and therefore whether the 
combination is meaningful as maintenance therapy in 
COPD), and also to verify the long-term impact of 
combination therapy on different clinical outcomes. 
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